Viscosupplementation Market Research, 2031
The global viscosupplementation market was valued at $4.4 billion in 2021, and is projected to reach $10.9 billion by 2031, growing at a CAGR of 9.5% from 2022 to 2031.Viscosupplementation is a minimally invasive treatment option for osteoarthritis patients. In a treatment called viscosupplementation, hyaluronic acid is injected into the patient's knee joint. The fluids of the joints and eyes contain large concentrations of hyaluronic acid, a naturally occurring lubricant. This fluid is crucial in lowering inflammation and pain in arthritic joints like the knee. There are three types of viscosupplementation by product which includes, single injection viscosupplementation, three injection viscosupplementation and five injection viscosupplementation. Application of viscosupplementation includes knee osteoarthritis, hip osteoarthritis, hand osteoarthritis and others. Others includes small joint osteoarthritis and shoulder osteoarthritis. Distribution channel for viscosupplementation are hospital pharmacies, retail pharmacies and online pharmacies.
Growth of the global viscosupplementation market size is majorly driven by rise in prevalence of osteoarthritis, rise in geriatric population and increase in number of product launch and product approval. Osteoarthritis is one of the most common forms of arthritis. According to Centers for Disease Control and Prevention, in 2019, it was reported that approximately 32.5 million (1 in 7 U.S. adults) people are diagnosed with osteoarthritis. The increasing prevalence of osteoarthritis has reached an alarming proportion due to an increasingly chronic disease such as obesity, diabetes, and heart disease. In addition, lack of physical activity such as exercise, surge the need for treatment of knee and hip osteoarthritis and drive the market growth. Geriatric population is more susceptible to osteoarthritis, and hence rise in geriatric population is the key contributing factor to the global viscosupplementation market share.
The global geriatric population has increased significantly, and is more vulnerable to knee and hip osteoarthritis due to aging effect, which decreases the flexibility and strength of the cartilage. The change in cells and extracellular matrix of joint tissues is also observed in geriatric population, which further develops imbalance between anabolic and catabolic activity. According to United Nation, in 2019, it was reported there were 703 million population aged 65 years or above, across the world. It was estimated that the number of aging people is projected to double to 1.5 billion in 2050. As per the same source, it was observed that the global share of the population aged above 65 years or more increased from 6% in 1990 to 9% in 2019. According to the Government of Canada's statistics report, the Canadian geriatric population was 6,592,611 people in July 2019, accounting for 17.5% of the total population.
Rise in adoption of key strategies such as collaboration, acquisition, agreement, and partnership by viscosupplementation industry fuels the viscosupplementation market growth. For instance, in Feb 2020, Anikz Therapeutics. Inc. a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic Acid (HA) technology platform, announced the complete acquisition of Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients. This acquisition significantly enhances Anika’s commercial capabilities in the U.S. and accelerates its product platform strategy by further expanding our portfolio and pipeline across the joint preservation and restoration continuum.
On the other hand, high cost of hyaluronic acid and presence of alternative for knee osteoarthritis treatment are some factors that are anticipated to restrain the growth of the viscosupplementation market size.
Viscosupplementation Market Segmentation
The viscosupplementation market share is segmented into type, application and distribution channel and region. On the basis of product, the market is segmented into single injection viscosupplementation, three injection viscosupplementation and five injection viscosupplementation. On the basis of application, the market is bifurcated into knee osteoarthritis, hip osteoarthritis, hand osteoarthritis and others. On the basis of knee osteoarthritis market is divided into gender. On the basis of distribution channel, the market is classified into hospital pharmacies, retail pharmacies and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Viscosupplementation Market by Type
The single injection viscosupplementation segment dominated the market in 2021, and is expected to continue this trend during the viscosupplementation market forecast period, owing to rise in the number of product launch for single injection viscosupplementation and reduction of injection volume makes administration of single injection viscosupplementation easier for healthcare professionals and more comfortable for patients. In addition, rise in the adoption of key strategies such as collaboration, partnership and agreement by key players for viscosupplementation products anticipated to fuel the market growth.
Viscosupplementation Market by Application
The knee osteoarthritis segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to rise in the prevalence of knee osteoarthritis and rising geriatric population who is more susceptible to knee osteoarthritis. The aging population is more vulnerable to knee osteoarthritis due to aging effect, which decrease the level of water contain in cartilage and further decreases its ability to absorb shock and cushion. According to the Journal of PlumX Metrics, in 2020, it was reported that the global prevalence of knee osteoarthritis was 16% and 22.9% in population above the age of 15 years and 40 years, respectively.
Viscosupplementation Market by Distribution Channel
The hospital pharmacies segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to rise in number of hospitals and rise in expenditure by government to develop healthcare infrastructure. Moreover, rise in the expenditure by government to develop healthcare infrastructure anticipated to fuel the market growth. In addition, rise in the prevalence of knee osteoarthritis anticipated to fuel the market growth.
Viscosupplementation Market by Region
The North America market was dominant, in terms of revenue among other regions in 2021, owing to rise in product launch and product approval of viscosupplenmentation and high presence of viscosupplementation industry who manufactures viscosupplementation product. On the other hand, Asia-Pacific was the second-largest contributor in the market in 2021, and is expected to register fastest CAGR during the forecast period, owing to rise in expenditure by government organization to develop healthcare sector, and increase in geriatric population.
Some of the major companies that operate in the global viscosupplementation market include Seikagaku Corporation, Anika Therapeutics, Inc. APTISSEN, Avanos Medical, Inc., Bioventus, Chugai Pharmaceutical Corp., Fidia Farmaceutici S.P.A, Laboratoires VIVACY, LG Life Sciences Ltd., Miravo Healthcare, Neopharmed Gentili S.p.A., Sanofi, SingHealth Group., Smith & Nephew PLC, Viatris, Zimmer Biomet.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the viscosupplementation market analysis from 2021 to 2031 to identify the prevailing viscosupplementation market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the viscosupplementation market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global viscosupplementation market trends, key players, market segments, application areas, and market growth strategies.
Viscosupplementation Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 10.9 billion |
 Growth Rate | CAGR of 9.5% |
 Forecast period | 2021 - 2031 |
 Report Pages | 300 |
 By Type |
|
 By Application |
|
 By Distribution channel |
|
 By Region |
|
 Key Market Players | Fidia Farmaceutici S.P.A, Avanos Medical, Inc., Anika Therapeutics, Inc., Chugai Pharmaceutical Corp., Sanofi, LG Life Sciences Ltd., Miravo Healthcare, Bioventus, Seikagaku Corporation, aptissen |
Analyst Review
Viscosupplementation is a procedure in which a thick fluid called hyaluronate is injected into the knee joint. It is one of the treatment procedures to relieve osteoarthritis. Viscosupplementation market is driven by factors including rise in geriatric population, rise in prevalence of osteoarthritis and increase in adoption of minimally invasive procedures.
Rise in adoption of key strategies such as collaboration, acquisition, agreement, and partnership by key players of viscosupplementation fuels the growth of market. For instance, in Feb 2020, Anikz Therapeutics. Inc. a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic Acid (HA) technology platform, announced the complete acquisition of Arthrosurface, a leading, privately-held provider of joint surface and preservation solutions for active patients. This acquisition significantly enhances Anika’s commercial capabilities in the U.S. and accelerates its product platform strategy by further expanding portfolio and pipeline across the joint preservation and restoration continuum.
Moreover, in August 2021, Seikagaku Corporation, a pharmaceutical company announced the launch of HyLink, an Intra-Articular Single-Injection viscosupplement for the Treatment of Knee Osteoarthritis in Taiwan.
The top companies that hold the market share in viscosupplementation market Seikagaku Corporation, Anika Therapeutics, Inc. APTISSEN, Avanos Medical, Inc., Bioventus, Chugai Pharmaceutical Corp., Fidia Farmaceutici S.P.A, Laboratoires VIVACY, LG Life Sciences Ltd., Miravo Healthcare, Neopharmed Gentili S.p.A., Sanofi, SingHealth Group., Smith & Nephew PLC, Viatris, Zimmer Biomet.
Asia-Pacific is expected to register highest CAGR of 10.3% from 2022 to 2031, owing to rise in expenditure by government organization to develop healthcare sector, and increase in geriatric population.
The key trends in the viscosupplementation market are rise in prevalence of osteoarthritis, rise in geriatric population and increase in number of product launch and product approval.
The base year for the report is 2021.
Yes, viscosupplementation market companies are profiled in the report
The total market value of viscosupplementation market is $4,426.4 million in 2021.
The forecast period in the report is from 2022 to 2031
The market value of viscosupplementation market in 2022 was $4,830.1 million
Loading Table Of Content...
